D. Keith  Grossman net worth and biography

D. Grossman Biography and Net Worth

CEO of Nevro
D. Keith Grossman was named CEO and President of Nevro in March of 2019. Mr. Grossman has over 30 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, Chief Executive Officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Vice Chairman of Alcon, Inc. and Chairman of Outset Medical, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc and a number of privately held medical device companies. Mr. Grossman received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

What is D. Keith Grossman's net worth?

The estimated net worth of D. Keith Grossman is at least $57,437.52 as of September 1st, 2021. Mr. Grossman owns 4,584 shares of Nevro stock worth more than $57,438 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Grossman may own. Learn More about D. Keith Grossman's net worth.

How do I contact D. Keith Grossman?

The corporate mailing address for Mr. Grossman and other Nevro executives is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. Nevro can also be reached via phone at (650) 251-0005 and via email at [email protected]. Learn More on D. Keith Grossman's contact information.

Has D. Keith Grossman been buying or selling shares of Nevro?

D. Keith Grossman has not been actively trading shares of Nevro over the course of the past ninety days. Most recently, on Tuesday, March 8th, D Keith Grossman bought 3,200 shares of Nevro stock. The stock was acquired at an average cost of $63.59 per share, with a total value of $203,488.00. Learn More on D. Keith Grossman's trading history.

Who are Nevro's active insiders?

Nevro's insider roster includes Michael DeMane (Director), D. Grossman (CEO), Kevin O'Boyle (Director), Kashif Rashid (General Counsel), and Elizabeth Weatherman (Director). Learn More on Nevro's active insiders.

Are insiders buying or selling shares of Nevro?

During the last twelve months, Nevro insiders bought shares 1 times. They purchased a total of 7,500 shares worth more than $171,600.00. The most recent insider tranaction occured on June, 7th when Director Shawn Mccormick bought 7,500 shares worth more than $171,600.00. Insiders at Nevro own 3.2% of the company. Learn More about insider trades at Nevro.

Information on this page was last updated on 6/7/2023.

D. Keith Grossman Insider Trading History at Nevro

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2022Buy3,200$63.59$203,488.00View SEC Filing Icon  
8/13/2021Buy7,000$105.07$735,490.00View SEC Filing Icon  
See Full Table

D. Keith Grossman Buying and Selling Activity at Nevro

This chart shows D Keith Grossman's buying and selling at Nevro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nevro Company Overview

Nevro logo
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $11.61
Low: $11.50
High: $12.22

50 Day Range

MA: $14.16
Low: $12.07
High: $17.33

2 Week Range

Now: $11.61
Low: $11.49
High: $34.86

Volume

346,380 shs

Average Volume

474,770 shs

Market Capitalization

$425.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89